대학원

정상택 교수

정상택 교수

정상택 / Sang Taek Jung

  • 소속의과학과
  • 직위부교수
  • 세부전공항체 및 의료용 단백질 공학
  • 연구실위치의과대학 본관 613호
  • 구내전화번호02-2286-1422
  • 팩스
  • 이메일sjung@korea.ac.kr
학력사항
199303 - 199702 서울대학교 공학사
199703 - 199902 서울대학교 공학석사
200408 - 200908 University of Texas at Austin 공학박사
교육 및 경력사항
199812 - 200104 녹십자 종합연구소, 연구원
200105 - 200403 삼양제넥스 생명공학연구소, 연구원
200908 - 201005 University of Texas at Austin, Postdoctoral Research Fellow
201006 - 201105 Caltech, Postdoctoral Research Fellow
201106 - 201208 University of Texas at Austin, Research Associate (Staff Scientist)
201209 - 201902 국민대학교 응용화학과, 부교수
학술활동
201209 - 현재 한국생물공학회 평의원
201301 - 201712 한국공업화학회 생물공학분과 운영위원/학술간사
201301 - 201712 한국단백질학회 운영위원/학술간사
201401 - 현재 한국항체소사이어티 운영위원/부회장
201501 - 현재 한국미생물생명공학회 운영위원/학술간사
대표논문
1. M. Jo, B. Hwang, H. W. Yoon, S. T. Jung* (2018) “Escherichia coli Inner Membrane Display System for High-Throughput Screening of Dimeric Proteins”, Biotechnology and Bioengineering, 115, 2849-2858.
2. S. H. Son, S.-I. Baek, M.-S. Ju, S.-G. Han, S. T. Jung, Y. G. Yu (2018). "Development of Single-Chain Antibodies Specific to Lysophosphatidic Acid Receptor2.", Bulletin of Korean Chemical Society, 39:4, 489-494.
3. M. Jo, H. S. Kwon, K.-H. Lee, J. C. Lee, S. T. Jung* (2018) “Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance”, mAbs, 2:10, 278-289.
4. S. Chauhan, C. Y. Hou, S. T. Jung, T. J. Kang (2017) “Detection and purification of backbone-cyclized proteins using a bacterially expressed anti-myc-tag single chain antibody, Analytical Biochemistry, 532, 38-44.
5. M.-S. Ju, S.-W. Min, S. M. Lee, H. S. Kwon, J. C. Park, J. C. Lee, S. T. Jung* (2017) “A synthetic library for rapid isolation of humanized single-domain antibodies”, Biotechnology and Bioprocess Engineering, 22:3, 239-247.
6. S.-G. Han, S. Ko, W.-K. Lee, S. T. Jung*, Y. G. Yu* (2017) “Determination of the endothelin-1 recognition sites of endothelin receptor type A by the directed-degeneration method”, Scientific Reports, 7, 7677.
7. H. Park, H. W. Yoon, S. T. Jung*, (2016) “The highly evolvable antibody Fc domain, Trends in Biotechnology, 34:11, 895-908.
8. M. Jo, S. T. Jung* (2016) “Engineering therapeutic antibodies targeting G-protein-coupled receptors”, Experimental and Molecular Medicine, 48, e207.
9. M.-S. Ju, J.-H. Na, Y. G. Yu, J.-Y. Kim, C. Jeong, S. T. Jung* (2015) “Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding”, Molecular Immunology, 67, 350-356.
10. S. H. Ko, S. T. Jung* (2015) “Engineering antibodies for dual specificity and enhanced potency”, Biotechnology and Bioprocess Engineering, 20, 201-210.
11. S. T. Jung*, T. H. Kang, D. I. Kim (2014) “Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding”, Biotechnology and Bioprocess Engineering, 19, 780-789.
12. M.-S. Ju, S. T. Jung*, (2014) “Aglycosylated full-length IgG antibodies steps toward next-generation immunotherapeutics, Current Opinion in Biotechnology, 30, 128-139.
13. Laserson, U., F. Vigneault, D. Gadala-Maria, G. Yaari, M. Uduman, J. A. Vander Heiden, W. Kelton, S. T. Jung, Y. Liu, J. Laserson, R. Chari, J.-H. Lee, I. Bachelet, B. Hickey, E. Lieberman-Aiden, B. Hanczaruk, B. B. Simen, M. Egholm, D. Koller, G. Georgiou, S. H. Kleinstein, and G. M. Church, (2014) ” High-resolution antibody dynamics of vaccine-induced immune responses”, Proceedings of the National Academy of Sciences USA (PNAS), 111:13, 4928-4933.
14. S. T. Jung*, (2013) “Tailoring immunoglobulin Fc for highly potent and serum-stable therapeutic antibodies”, Biotechnology and Bioprocess Engineering, 18:4, 623-636.
15. J.-H. Na, M.-S. Joo, W.-K. Lee, H. Shim, S.-H. Lim, S. T. Jung, Y. G. Yu, (2013) ”Development of a single chain antibody using a phage display cloning method for the detection of 2,4-dinitrotoluene”, Bulletin of Korean Chemical Society, 34:2, 460-464.
16. H. H. Lee, S. T. Jung, (2013) ”Overexpression, crystallization, and preliminary X-ray crystallographic analysis of β-N-acetylglucosaminidase from Thermotoga maritime by the Tm0809 gene”, Acta Crystallographica Section F, 69:Pt2, 115-117.
17. Y. Wine, D. R. Boutz, J. J. Lavinder, A. E. Miklos, R. A. Hughes, K. H. Hoi, S. T. Jung, A. P. Horton, A. D. Ellington, E. M. Marcotte, G. Georgiou, (2013) ”Molecular deconvolution of the polyclonal antibody serum response”, Proceedings of the National Academy of Sciences USA (PNAS), 110:8, 2993-2998.
18. S. T. Jung, W. Kelton, T. H. Kang, D. T. Ng, J. T. Andersen, I. Sandlie, C. A. Sarkar, G. Georgiou, (2013) ”Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity”, ACS Chemical Biology, 8:2, 368-375.
19. H. K. Yoon, S. T. Jung, J. Kim, T. H. Yoo, (2012) “Recent Development of Highly Sensitive Protease Assay Methods: Signal Amplification through Enzyme Cascades”, Biotechnology and Bioprocess Engineering, 17, 1113-1119.
20. E. M. Brustad, V. S. Lelyveld, C. D. Snow, N. Crook, S. T. Jung, F. M. Martinez, T. J. Scholl, A. Jasanoff, F. H. Arnold, (2012) “Structure-guided directed evolution of highly selectively P450-based magnetic resonance imaging sensors for dopamine and serotonin”, Journal of Molecular Biology, 422:2, 245-262.
21. M. J. Borrok, S. T. Jung, T. H. Kang, A. F. Monzingo, G. Georgiou, (2012) ”Revisiting the role of glycosylation in the structure of human IgG Fc”, ACS Chemical Biology, 7:9, 1596-1602.
22. S. T. Jung, T. H. Kang, W. Kelton, G. Georgiou, (2011) “Bypassing glycosylation: Engineering aglycosylated full length IgG antibodies for human therapy, Current Opinion in Biotechnology, 22:6, 858-867.
23. S. T. Jung, R. Lauchli, F. H. Arnold, (2011), “Cytochrome P450: taming a wild type enzyme”, Current Opinion in Biotechnology, 22:6, 809-817.
24. J. Qiu, S. T. Jung, G. Georgiou, H. Hang, (2010), “Enrichment of Escherichia coli spheroplasts displaying scFv antibodies specific for antigens expressed on the human cell surface”, Applied Microbiology and Biotechnology, 88:6, 1385-1391.
25. S. T. Jung, T. H. Kang, G. Georgiou (2010), “Efficient expression and purification of human aglycosylated Fcγ receptors in Escherichia coli”, Biotechnology and Bioengineering, 197:1, 21-30.
26. S. T. Jung, S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie, P. W. Tucker, G. Georgiou (2010), “Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells”, Proceedings of the National Academy of Sciences USA (PNAS), 107:2, 604-609.
27. Highlighted in Nature Biotechnology (2010), 28:1, 45, “Research Highlights”, “Receptor-selective aglycosylated Abs”,
· Highlighted in Nature SciBX (Science Business eXchange) (2010), 3:3, Jan 21, 2010 issue, “Cover Story”, “mAbs that live long and prosper”,
http://www.nature.com/scibx/journal/v3/n3/full/scibx.2010.73.html

목록